<DOC>
	<DOCNO>NCT00966004</DOCNO>
	<brief_summary>The purpose study evaluate effect YM178 patient overactive bladder 12-week administration .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy YM178 Patients With Overactive Bladder</brief_title>
	<detailed_description>This study examine superiority YM178 placebo evaluate safety pharmacokinetics YM178 patient overactive bladder , compare efficacy safety YM178 tolterodine , control drug , without non-inferiority test . The drug administration period 14 week total , consist 2 week placebo ( pre-investigation period ) 12 week investigational drug ( treatment period ) .</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Patient symptom overactive bladder least 24 week initiation preinvestigational period Patient capable walk lavatory without assistance measure urine volume him/herself Patient average frequency micturition 8 time per 24hour period Written inform consent obtain Patients without experience urge incontinence informed consent Patients give clear diagnosis stress incontinence Patients transient symptom suspect overactive bladder ( drug induce , psychogenic , etc ) Patients complicate urinary tract infection , urinary stone , and/or interstitial cystitis Patients previous history recurrent urinary tract infection Patients complicate history bladder tumor prostatic tumor Patients confirm postvoid residual volume ≥ 100 mL clinically significant low urinary tract obstructive disease Patients give medication treatment low urinary tract obstructive disease within 4 week preinvestigational period Patients indwell catheter practice intermittent selfcatheterization Patients give radiotherapy influence urethral function , thermotherapy benign prostatic hyperplasia Patients give surgical therapy may influence urethral function within 24 week preinvestigational period Patients uncontrolled hypertension pulse rate ≥ 110 bpm &lt; 50 bpm Patients polyuria exceed 3000 mL mean daily urine volume Patients meet following examination Patients abnormal electrocardiogram judge inappropriate subject ECG Evaluation Committee Patients AST ( GOT ) ALT ( GPT ) 2.5 time high upper limit normal range ( 100 IU/L ) Patients blood creatinine level ≥ 2.0 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Urge incontinence</keyword>
	<keyword>YM178</keyword>
	<keyword>Overactive Bladder</keyword>
	<keyword>Urgency</keyword>
	<keyword>Urinary incontinence</keyword>
	<keyword>mirabegron</keyword>
	<keyword>Micturition</keyword>
</DOC>